

ABSTRACT

An object of the present invention is to develop gene-modified measles viruses (rMV-SLAMblind and rMV-V(-)-SLAMblind) that do not recognize SLAM as a tool for a medical treatment for tumors. The present invention provides a pharmaceutical
5 composition for inducing cell-mediated immunity against a tumor cell to subject the tumor cell to medical treatment, the pharmaceutical composition containing an oncolytic gene-modified measles virus, and also provides a method of inducing cell-mediated immunity against a tumor cell remaining in a living body that could not be eliminated even by direct introduction of an oncolytic gene-modified measles virus, or against a
10 tumor cell that has metastasized or recurred, the method including directly introducing an oncolytic gene-modified measles virus into a tumor cell as a medical treatment target to cause cell death.

FIG. 1